TAF is a new nucleoside reverse transcriptase inhibitor (NRTI), which can reduce the content of hepatitis B virus (HBV) and improve liver function. After entering hepatocytes, the drug can be hydrolyzed into tenofovir. Tenofovir is subsequently phosphorylated by intracellular kinases to form tenofovir diphosphate with pharmacological activity. Tenofovir diphosphate is integrated into virus DNA by HBV reverse transcriptase, which leads to the interruption of DNA chain synthesis.
It is estimated that there are as many as 35-4 million patients with hepatitis B worldwide, which can lead to cirrhosis and is the direct cause of 8% of the world's primary liver cancer. In China, it is conservatively estimated that there are 1 million people infected with chronic hepatitis B virus (HBV) in the country's population of 1.3 billion, accounting for about one third of the global HBV carriers, and the incidence of hepatitis B in China is still rising, but the appearance of TAF has ushered in new hope.
what are the versions of TAF
1. The original drug of American Gilead. The price is 28 yuan/tablet, and the monthly drug price is about 84 yuan.
2. Laos version, which is not authorized, is low in price, and there are many counterfeit drugs on the market at present.
3. mylan version in India. Authorized by American Gilead Company, the price is about one bottle in 2 yuan.
experimental results
the data released at the 217 international hepatology conference show that TAF can maintain a high virus inhibition rate after 96 weeks of medication, and no drug resistance is found, and it has less influence on renal function and bone mineral density parameters. In addition, after 96 weeks of switching from TDF to TAF, the patient still maintained virological inhibition, the serum ALT level returned to normal, and the parameters of renal function and bone mineral density improved after 24 weeks of switching. After analyzing 541 patients who completed 96 weeks' treatment in Study 18 and Study 11, it was found that among 18 patients who switched from TDF to TAF, virological inhibition was maintained at 96 weeks, and the ALT level returned to normal after 24 weeks' dressing change.